Company news

Alvotech news in 2025

Alvotech's news releases, calls and decks from 2025, newest first.

View company

Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today

May 18, 2025

Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm

May 18, 2025

Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm

May 15, 2025

Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada

May 8, 2025

Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

May 7, 2025

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025

May 6, 2025

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 6, 2025

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 6, 2025

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

May 4, 2025

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8: 00 am EDT

May 1, 2025

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8: 00 am EDT (14: 00 CET)

May 1, 2025

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

March 26, 2025

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

March 25, 2025

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

March 25, 2025

Alvotech Reports Record Results for 2024 and Provides Business Update

March 25, 2025

Alvotech Reports Record Results for 2024 and Provides Business Update

March 25, 2025

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

March 19, 2025

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

March 17, 2025

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

March 17, 2025

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

March 6, 2025

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8: 00 am ET

February 23, 2025

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

February 20, 2025

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

February 17, 2025

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

January 26, 2025

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

January 26, 2025

← Newer news releases

Calls in 2025

Decks in 2025